Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai
NCT07220863
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Prospective observational study evaluating the safety and accuracy of Feminai 1.0, an at-home adhesive patch that measures skin temperature and electrical impedance to map each breast. Up to 300 women (ages 25-75) undergoing screening will have one study visit; Feminai results will be compared with mammography and, when available, biopsy to assess sensitivity and negative predictive value. Feminai is investigational, intended to support clinical decision-making, and does not replace standard diagnostic tests.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer Awareness
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 25 to 75 years
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Feminai
- Last updated on ClinicalTrials.gov
- October 24, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Solis Mammography Frisco at Stonebriar · Frisco, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.